MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2017.10.014

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2017

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski Patrick, Wozniak Agnieszka, Escudier Bernard, Rutkowski Piotr, Anthoney Alan, Bauer Sebastian, Sufliarsky Jozef, van Herpen Carla, Lindner Lars H, Grünwald Viktor, Zakotnik Branko, Lerut Evelyne, Debiec-Rychter Maria, Marréaud Sandrine, Lia Michela, Raveloarivahy Tiana, Collette Sandra, Albiges Laurence

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-).

EXPERIMENTAL

DESIGN

Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed to MET+/MET- sub-cohorts by the sequencing of exons 16-19 of the MET gene in tumour tissue. The primary end-point was objective response rate (ORR). If at least two of the first 12 eligible and evaluable MET+ patients achieved a confirmed partial response (PR) or complete response (CR) (in accordance with the Response Evaluation Criteria in Solid Tumours, version 1.1), a maximum of 35 patients were enrolled. Secondary end-points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), PFS rate (PFSR), overall survival (OS) and safety.

RESULTS

Forty-one patients provided consent, of whom 23 were eligible, treated and evaluable. In four MET+ patients, two achieved PR and one had stable disease (SD) (ORR 50%; 95% confidence interval [CI]: 6.8-93.2), DOR was 21.8 and 37.3 months, 1-year PFSR: 75.0% (95% CI: 12.8-96.1) and 1-year OS: 75.0% (95% CI: 12.8-96.1). Among 16 MET- patients, one achieved a PR lasting more than 9.9 months and 11 had SD (ORR: 6.3%; 95% CI: 0.2-30.2), 1-year PFSR: 27.3% (95% CI: 8.5-50.4) and 1-year OS: 71.8% (95% CI: 41.1-88.4). Among three patients with unknown MET status (MET?) due to technical failure, one achieved PR lasting more than 6.9 months, and one had SD (ORR 33.3%, 95% CI: 0.8-90.6), 1-year PFSR: 66.7% (95% CI: 5.4-94.5) and 1-year OS: 100%. MET amplification was found post hoc in one MET+ patient (PR, DOR: 37.3 months), and one MET- case who had SD. Common treatment-related adverse events were oedema (47.8%), fatigue (47.8%), nausea (39.1%), diarrhoea (39.1%) and blurred vision (34.8%).

CONCLUSION

Crizotinib is active and well tolerated in advanced, metastatic PRCC1, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification. Sporadic, durable responses are also seen in MET- and MET? cases, suggesting the presence of other alterations of MET or alternative pathways.

Для цитирования: Schöffski Patrick, Wozniak Agnieszka, Escudier Bernard, Rutkowski Piotr, Anthoney Alan, Bauer Sebastian, Sufliarsky Jozef, van Herpen Carla, Lindner Lars H, Grünwald Viktor, Zakotnik Branko, Lerut Evelyne, Debiec-Rychter Maria, Marréaud Sandrine, Lia Michela, Raveloarivahy Tiana, Collette Sandra, Albiges Laurence. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.. European journal of cancer (Oxford, England : 1990). 2017. DOI: 10.1016/j.ejca.2017.10.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.